Genetic testing in cancer: a systematic review of patient reported measures
Kelsie RaspiniD, Daisy Nowakowski, Joanne L. DickinsoniD, Jessica K. RoydhouseiD
Abstract
Advances in genomic technologies have driven a substantial shift in cancer care. Understanding patients experience of care and their associated outcomes is essential to effectively delivering precision care. These outcomes are usually evaluated through patient reported measures (PRMs), rather than administrative data. We conducted a systematic review of the literature to identify, describe and summarise the PRMs employed when patients with cancer underwent genetic testing. Search terms included cascade screening OR carrier screening OR genetic testing OR genetic counselling AND cancer AND patient reported outcomes AND NOT Review (Publication Type). A total of 474 articles were identified and following full text review, 46 studies were included for data extraction. We identified 98 measures, with 32 of them being genetics specific PRMs. These PRMs focussed on knowledge of genetics, perceptions, concerns, interest and acceptability. Majority of the included studies were conducted in the United States (n=27; 58.7%) and included breast cancer patients (nbreast=14; nbreast&ovarian=13). Given differences in legislative frameworks regarding the use of genetic information across countries, most included studies were conducted in countries where discrimination based on genetic features is illegal. It was also evident that studies in cancers other than breast are warranted and could inform standardised collection of key outcomes across the cancer spectrum. This review has identified, described and summarised what types of measures have been used when patients with cancer have undergone genetic testing and has highlighted the urgent need for development of additional PRMs in this area, particularly in cancers other than breast. Summary of Research ArticleWe identified, described and summarised the measures published studies have used to gather a patients experience and outcomes related to genetic testing for their cancer. Our review identified 46 studies that used 98 different measures, 32 of which were associated with genetics specific topics, such as knowledge of genetics, perceptions, concerns, interest and acceptability of genetic testing. This review has highlighted that most studies have been conducted in the United States and included mainly breast cancer or breast and ovarian cancer patients.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Title: A Randomized Hybrid Type I Effectiveness-Implementation Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer (eREACH2): study protocol
Evelyn Mastaglio, Brian Lee Egleston, … Angela R. Bradbury·BMC CancerPeer-reviewed·Jul 31, 2026
- What tools do men need to make an informed decision about germline genetic testing for prostate cancer? A qualitative and survey study
Kelsie Raspin, Larissa Bartlett, … Joanne L. Dickinson·medRxiv·May 7, 2026
- A Randomized Non-Inferiority Trial of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer (eREACH2)
Kimberley T. Lee, Brian Lee Egleston, … eREACH2 Group·Journal of Clinical OncologyPeer-reviewed·May 27, 2026
- eREACH: A randomized trial of digital alternatives to genetic counseling for metastatic cancer
Kimberley T. Lee, Brian Lee Egleston, … Angela R. Bradbury·medRxiv·Oct 1, 2025
- Socioeconomic and Clinical Determinants Driving Access to BRCA Genetic Testing in Cancer : A Case-Control Study Using Observational Electronic Health Records Across Multiple Sites
Qiang Yang, Chengrong Wang, … Rui Yin·medRxiv·May 21, 2026
- BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial
Bethany Torr, Christopher Iain Jones, … Clare Turnbull·British Journal of CancerPeer-reviewed·Sep 30, 2024